Nykode Therapeutics AS (FRA:5VB)

Market Cap	90.84M +21.9%
Revenue (ttm)	6.26M +68.1%
Net Income	-9.38M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	85
Average Volume	4
Open	0.2258
Previous Close	0.1989
Day's Range	0.2258 - 0.2258
52-Week Range	0.0859 - 0.2876
Beta	n/a
RSI	62.92
Earnings Date	Feb 25, 2026

About Nykode Therapeutics AS

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 i...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2006
• Employees: 62
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5VB

Financial Performance

In 2024, Nykode Therapeutics AS's revenue was $9.16 million, a decrease of -31.26% compared to the previous year's $13.32 million. Losses were -$38.82 million, 10.4% more than in 2023.

Financial numbers in USD